Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorSven Schneider, MD
About this trial
Nasal allergen study in patients aged 60+ with or without current respiratory allergy
Eligibility criteria
This trial accepts healthy volunteersQualifiers
General inclusion criteria Age ≥ 60 years Willingness to participate in the study and to follow the protocol Written informed consent Standard healthcare insurance Subjects should be available during the entire study period
Disqualifiers
- Evidence of acute, chronic, malignant or general diseases-assessed by asking the patient
A History of anaphylaxis
Utilization of leukotriene modifiers or long-acting antihistamines
Chronic or intermittent use of oral, inhaled, intramuscular or intravenous corticosteroids
Trial population
Patients aged ≥ 60 years with or without current or former allergy
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
152 Participants
are grouped into 3 trial groupsGroup A: Ongoing (symptoms min 3 years)
Group B: Previous (no symptoms past 3 years)
Group C: No (never symptoms)
Trial outcomes
Primary outcomes
1
Nasal IgG4
To demonstrate that Bet v 1-specific nasal IgG4 responses 5 weeks after controlled nasal birch pollen provocation are significantly higher in subjects aged ≥60y without ongoing respiratory allergic symptoms with a history of allergy (group1) as compared to age-matched subjects currently suffering from allergic rhinoconjunctivitis (group 2).
Time frame
5 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Sven Schneider, MD
Lead sponsor
Medical University of Vienna
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: